Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Dr. Sumant Ramachandra as President, Research and Development.
Prior to Synta, Dr. Ramachandra was Senior Vice President, Research and Development (R&D), Regulatory and Medical Affairs, and Chief Scientific Officer of Hospira, a specialty pharmaceuticals and medical device company. At Hospira, Dr. Ramachandra led a 1,200 person R&D organization and was recognized for his achievements and contributions as a healthcare leader in PharmaVoice’s “100 of the Most Inspiring People,” Diversity MBA’s “Top 100 Under 50 Diverse Executive Leaders,” and Chicago Business’ “Crain’s 40-under-40.”
Prior to joining Hospira in 2008, Dr. Ramachandra was Vice President and oncology portfolio therapeutic area leader at Merck & Co. (formerly Schering-Plough), and prior to Merck/Schering-Plough he was therapeutic area head for medical oncology at Pfizer (formerly Pharmacia). At these companies, Dr. Ramachandra drove the development, regulatory approval, and market expansion studies for numerous oncology products.
“Sumant brings a broad range of development and regulatory leadership experience, as well as a unique perspective having led both oncology development at large pharmaceutical companies, and the broader range of R&D functions at a large, global specialty pharma company,” said Safi Bahcall, President and CEO, Synta. “Sumant’s experiences with a wide range of drugs, manufacturers, pharma companies, payors, providers, and regulatory agencies will enhance our ability to realize the full potential of our product pipeline to benefit patients.”“The programs at Synta can change the treatment of many types of cancers,” said Dr. Ramachandra. “In addition, Synta’s culture of innovation, collaboration, and commitment to speed and excellence in execution are exciting and critical to success in our industry. I am very much looking forward to being part of the Synta team and contributing to bringing these new drugs to cancer patients.” Dr. Ramachandra received a bachelor's degree in biochemistry from Rutgers University, and M.D. and Ph.D. degrees from the University of Medicine and Dentistry-New Jersey Medical School. He conducted his residency at the Harvard-affiliated Massachusetts General Hospital (MGH). Dr. Ramachandra also earned a master's of business administration from the Wharton Business School at the University of Pennsylvania.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts